CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
People with high frequency episodic migraine (HFEM) and chronic migraine (CM) who are typically excluded from randomised controlled trials (RCTs) of anti-CGRP therapies responded as well to galcanezumab over a 12-month period as those who took part in pivotal clinical trials of the drug, according to real world data from the Galca-Only Registry.1 Of the …
Read more »In complex patients with multiple treatment failures, good responder rates are seen with anti-CGRP mAbs irrespective of previous poor response to botulinum toxin A (BTX-A), but dual therapy with anti-CGRP mAbs and botulinum toxin A does not appear to add more benefit compared to anti-CGRP mAb monotherapy.1 These were the findings from a real world …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
